Anavex Life Sciences Corp (NASDAQ:AVXL) announced that long-term clinical study results from the U.S. ANAVEX2-73-RS-001 study demonstrate a disease-modifying effect of ANAVEX2-73 (blarcamesine) for adult patients with Rett syndrome.
In the U.S. ANAVEX2-73-RS-001 trial, of all 25 patients who both started and completed the randomized, double-blind, placebo-controlled study, 24 patients voluntarily enrolled in the 12-week open-label extension (OLE) study. The 12-week extension study was subsequently further extended to 36 weeks.
The data shows that blarcamesine exhibited both symptomatic and disease-modifying effects for Rett syndrome in a clinical setting.
Continued improvement from the drug was observed from the start of the double-blind study to the end of the open-label extension part for patients continuing on blarcamesine. Patients previously on placebo who switched to blarcamesine experienced improvement.
Additionally, disease progression was also reduced with long-term treatment with blarcamesine.
Patients assigned first to blarcamesine in the double-blind part of the study and who continued during the OLE study had a statistically significant reduction in disease severity and progression compared to patients assigned first to placebo and then switched to blarcamesine.
Price Action: AVXL shares are down 1.67% at $7.95 on the last check Wednesday.
